3,4,5-trihydroxybenzohydroxamic acid
Also Known As:
VF 122; VF-122
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Related Diseases
1. | Hepatocellular Carcinoma (Hepatoma)
01/01/1985
- " DBD in combination with VF-122 exhibited additive lethality against hepatoma cells in culture. " 12/01/1982
- " Proliferating and resting hepatoma 3924A cells recovered from sublethal and potentially lethal damage induced by VF 122." 12/01/1982
- " Exponentially growing hepatoma 3924A cells were more sensitive to VF 122 than were plateau-phase cultures. " 12/01/1982
- " In contrast, hydroxyurea killed only exponentially growing 3924A hepatoma cells, exhibiting an exponential plateau dose-response curve without achieving achieving an IC50 value at concentrations from 1 to 200 mM. In synchronized cultures, VF 122 (1 MM for 1 hr) was toxic for cells in mid and late G1 phase, in early and mid S phase, and, to a lesser degree, in G2 phase, Hydroxyurea (10 mM for 1 hr) killed cells only in S phase. " 12/01/1982
- " 3, 4, 5-Trihydroxybenzohydroxamic acid (VF 122), an inhibitor of ribonucleotide reductase, killed rat hepatoma 3924A cells in tissue cultured after 7 days of incubation. "
|
2. | Neoplasms (Cancer)
|
|
Related Drugs and Biologics